SMSbiotech, founded in 2015, is a pre-clinical, late-stage biotech company. Through a combination of hard work and over 30 years of experience in research and applications, they have been able to introduce a new proprietary technology that will change the way the life science industry approaches the research of cells, drugs, and toxins. Based on their patented, revolutionary, adult stem cell research technologies, new potential treatments can be tested earlier than with traditional methods, and cost-effectively.

The SMSbiotech platform technology will penetrate the regenerative medicine and bio-manufacturing markets and lay the groundwork for developing alternative, more efficient, and relevant treatments and medications.